RyboDyn
Unlocking the dark proteome for high-resolution immunotherapies
* Data source: Crunchbase
- Founded
- 2022
- Employees*
- 2-10
- Funding to Date*
- $525,000
- Website
- www.rybodyn.com/
"Our genome makes RNA molecules that current sequencing technologies cannot detect. These molecules encode undiscovered human proteins (the dark proteome), providing an untapped source of disease-specific protein targets that will become foundational to the future of precision medicine"
The entire immuno-oncology field is orbiting around the same 30 targets and are hungry for new ones
RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our “targets-to-assets” therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.
More Companies
